Endocrine Abstracts

Background: Teprotumumab showed significant improvements vs placebo for the treatment of thyroid eye disease (TED) in clinical trials1,2 and is approved in the United States (US) but currently not in the EU. Differences exist in baseline patient demographics and characteristics between EU and US patients. Here we examine outcomes in these 2 cohorts.Methods: Data from the EU and US sites for patients in the teprotumumab group (n =121) from the in...